Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Market Cap	800.60M -18.9%
Revenue (ttm)	74.40M -38.0%
Net Income	-94.29M
EPS	-0.49
Shares Out	193.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,570
Open	n/a
Previous Close	4.130
Day's Range	n/a
52-Week Range	4.000 - 8.400
Beta	-1.23
RSI	12.10
Earnings Date	Mar 27, 2026

About Wuhan YZY Biopharma

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. Wuhan YZY Biopharma Co., Ltd. w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 106
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2496

Financial Performance

In 2025, Wuhan YZY Biopharma's revenue was 66.86 million, a decrease of -37.99% compared to the previous year's 107.81 million. Losses were -84.73 million, -13.18% less than in 2024.

Financial numbers in CNY